Sinopharm (01099): The net income attributable to the parent of China National Medicines Corporation (600511.SH) for the first half of the year was 1.001 billion yuan, a year-on-year increase of 1.62%.

Zhitong Finance · Aug 21 06:35

Sinopharm (01099) announced the performance of its subsidiary China National Medicines Corporation (China National Medicines Corporation) as of 2024...

Zhitong Finance APP news, Sinopharm (01099) announced the performance of its subsidiary China National Medicines Corporation as of June 30, 2024. The revenue was 24.747 billion yuan (RMB, same below), an increase of 2.55% year-on-year; the net income attributable to the shareholders of the listed company was 1.001 billion yuan, an increase of 1.62% year-on-year; and the basic earnings per share was 1.3261 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

国药控股(01099)：国药股份(600511.SH)中期归母净利润10.01亿元 同比增加1.62%

Sinopharm (01099): The net income attributable to the parent of China National Medicines Corporation (600511.SH) for the first half of the year was 1.001 billion yuan, a year-on-year increase of 1.62%.

Risk Disclaimer

Statement

国药控股(01099)：国药股份(600511.SH)中期归母净利润10.01亿元同比增加1.62%